FDA Grants Priority Review to Frontline Brentuximab Vedotin for Hodgkin Lymphoma

January 2, 2018 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for brentuximab vedotin in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma, according to a statement from the company developing the CD30-targeted antibody-drug conjugate, Seattle Genetics. The sBLA is based on findings from the phase III … (leggi tutto)